RCM
AGIO icon

Riverhead Capital Management’s Agios Pharmaceuticals AGIO Stock Holding History

Riverhead Capital Management’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-201
Closed -$14K – 1519
2019
Q1 		$14K Buy
201
+59
+42% +$3.44K ﹤0.01% 1482
2018
Q4 		$6K Sell
142
-7
-5% -$432 ﹤0.01% 1486
2018
Q3 		$11K Hold
149
– – ﹤0.01% 1546
2018
Q2 		$13K Buy
149
+77
+107% +$6.71K ﹤0.01% 1522
2018
Q1 		$6K Buy
+72
New +$5.57K ﹤0.01% 1530

Other funds holding AGIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Riverhead Capital Management's AGIO Position: Q2 2019 in Review

Riverhead Capital Management sold out of Agios Pharmaceuticals (AGIO) in Q2 2019, closing a stake of 201 shares — an estimated $14K sold.

Riverhead Capital Management first reported a position in AGIO in Q1 2018 and held it in 5 quarters. The position peaked at $14K in Q1 2019. 189 funds tracked by Wall St. Rank hold AGIO as of Q2 2019.

  • Riverhead Capital Management reported no remaining Agios Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Riverhead Capital Management sold 201 Agios Pharmaceuticals shares in Q2 2019, an estimated $14K.
  • Riverhead Capital Management first reported a position in Agios Pharmaceuticals in Q1 2018 and held it in 5 quarters.
  • Riverhead Capital Management's Agios Pharmaceuticals position peaked at $14K in Q1 2019.
  • 189 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q2 2019.

Based on Riverhead Capital Management's 13F filing for Q2 2019, filed 12 Aug 2019.